Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation

View Full Paper
Ask AI
Bookmark
Share

Authors

SFSaubia FathimaAAAli AlsugairTLTerra L. Lasho

Discussion

Loading...

Member takes

Overview

Analysis reveals myeloproliferative neoplasm mutations raise blast transformation risk in chronic myelomonocytic leukemia patients, suggesting implications for treatment options.

Key Points

  • Blast transformation risk increases among chronic myelomonocytic leukemia patients with myeloproliferative neoplasms mutations, highlighting potential treatment considerations.
  • In a cohort of 612 CMML patients, the presence of myeloproliferative neoplasm mutations was linked to a higher cumulative incidence of blast transformation.
  • Statistical analyses indicated that the presence of mutations in key genes like TP53 and variations in absolute neutrophil count impacted overall outcomes, influencing care strategies.
  • Results may enable personalized approaches for managing chronic myelomonocytic leukemia in patients with mutations, calling for further investigation into treatment effectiveness.

Cite This Study

Fathima et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d79dhttps://doi.org/10.1182/blood-2025-2067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia2025
  2. 2Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations2025
  3. 3Clinical features and outcomes of myelofibrosis patients with MPL mutations2025
  4. 4Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients2025
  5. 5Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center2025